Pharmacology Watch
RSSArticles
-
New PPI Mortality Data: Is There a Risk?
Are proton pump inhibitors associated with excess risk of mortality? That is the finding of a highly publicized study.
-
FDA Actions
In this section: FDA approves new amyotrophic lateral sclerosis, expands the indication for pembrolizumab, adds giant cell arteritis to the indication for tocilizumab, and green lights generic ADHD drug.
-
Ohio Attorney General Files Suit Against 5 Pharmaceutical Companies Over Opioids
The suit alleges fraudulent marketing that misled the state, prescribers, and patients about the risks of these medications.
-
Investigators Conclude Long-term Opioid Use Increases Dependency and Overdose Risks
Nationwide epidemic has raised questions regarding the long-term use of such medication for chronic pain conditions.
-
Researchers Offer Remedies for FDA’s Accelerated Approval Program
Once a drug receives accelerated approved, manufacturers are free to charge whatever they believe the market will bear without evidence that the drug affects disease progression.
-
FDA Actions
In this section: The agency approves new treatment for postmenopausal osteoporosis, greenlights generic treatment for hypercholesterolemia, give approval to a second biosimilar to infliximab, restricts the use of codeine and tramadol in children, and allows valbenazine to treat tardive dyskinesia.
-
Testing the Effects of Statins on Muscles
How common are statin-related muscle symptoms?
-
Association of Autism with Antidepressant Use During Pregnancy
Two new studies suggest that maternal use of antidepressants during pregnancy is not associated with autism.
-
PCSK9 Drug Improves Heart Outcomes
Although evolocumab and alirocumab lowered low-density lipoprotein better than statins, evidence of cardiovascular benefit had been lacking — until now.
-
FDA Actions
In this section: The agency approves exciting new treatment for multiple sclerosis, green lights an injection for atopic dermatitis, gives the go ahead to an add-on treatment for Parkinson's disease, and signs off on a drug for Duchenne muscular dystrophy.